OA09.05 A Phase 3 Study of Serplulimab Plus Chemotherapy as First-Line Treatment for Squamous Non-small-Cell Lung Cancer (ASTRUM-004)

Historically, treatment for squamous non-small-cell lung cancer (sNSCLC) was mostly based on chemotherapy. Adding PD-1/PD-L1 inhibitor to chemotherapy has demonstrated improved efficacy over chemotherapy alone in first-line treatment of unselected patient population with advanced or metastatic sNSCLC. However, preferred treatment options with a favorable benefit-risk ratio are still limited for advanced sNSCLC in the global setting. Here we report the results from a phase 3 study of serplulimab (a novel anti-PD-1 antibody) plus chemotherapy (carboplatin and nab-paclitaxel) in patients with locally advanced or metastatic sNSCLC who have not received previous systemic treatment.